Arne Burkhardt opened the bodies. What he found should have stopped everything. Vaccine-derived spike protein in heart tissue. In blood vessel walls. In brain tissue. In multiple organs across multiple cases. Not in one anomalous death. Consistently. Repeatedly. With inflammatory patterns and lymphocytic infiltrates that follow directly from the known mechanism of mRNA vaccination, widespread, systemic spike protein production that the manufacturers and regulators always claimed would stay local and resolve quickly. It did not stay local. It did not resolve quickly. Burkhardt found it persisting in the deceased, distributed throughout organ systems, accompanied by the exact tissue damage you would predict if you believed Sucharit Bhakdi’s warnings about endothelial cells producing spike protein and triggering immune attack from within. The mechanism is not complicated once you accept what the biodistribution data already showed. Lipid nanoparticles do not remain at the injection site. Pfizer’s own Japanese biodistribution study, obtained through freedom of information requests, showed accumulation in the liver, adrenal glands, ovaries, and beyond. When those nanoparticles reach tissue, cells take up the mRNA, produce spike protein, and display it on their surface. The immune system recognizes it as foreign and attacks. In the heart, that means myocarditis. In vessel walls, that means vascular inflammation. In the brain, that means neurological damage. Burkhardt’s autopsies are not speculation, they are the physical, histological confirmation of a mechanism that was biologically predictable and institutionally ignored. In many of these cases, no other plausible cause of death was identified. These were not people with terminal diagnoses or obvious competing explanations. They were people who died in proximity to vaccination, whose deaths were documented, whose tissues were examined by a trained pathologist, and whose organs showed the fingerprints of spike protein-driven inflammation. That is not a coincidence. That is evidence. And health agencies have responded to that evidence by downplaying it, dismissing Burkhardt’s methodology, discouraging thorough post-mortem investigation, and refusing any systematic, government-funded autopsy program that might produce data they cannot control. They knew the biodistribution data before a single dose was administered to the public. They had Pfizer’s own studies showing the lipid nanoparticles traveled. They authorized anyway. They mandated anyway. They silenced the clinicians and pathologists raising concerns anyway. And now, faced with autopsy findings that document spike protein in the organs of the dead, they respond not with investigation but with institutional silence and the quiet suppression of inconvenient science. That is not a public health apparatus functioning in good faith. That is an apparatus protecting itself. The dead cannot demand answers. The injured, many of whom carry the same spike-driven inflammatory damage in living tissue, are told their symptoms are unrelated, psychosomatic, or coincidental. Burkhardt’s work, alongside the vascular findings documented by Bhakdi and colleagues, represents a body of post-market evidence that should have triggered immediate regulatory review, mandatory autopsy protocols, and full transparency on biodistribution. Instead it has been buried, not by counter-evidence, not by superior data, but by institutional authority and the refusal to look. This is what burying evidence looks like. It does not always involve shredded documents or deleted files. Sometimes it looks like a regulatory agency that simply never funds the study, never mandates the autopsy, never convenes the independent panel and then points to the absence of data it refused to generate as proof that there is nothing to find.